Apellis Pharmaceuticals (APLS) , in collaboration with Sobi, reported positive one-year results from the mid-stage study evaluating systemic pegcetacoplan to treat post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).Pegcetacoplan is being developed as a targeted C3 therapy that addresses the cause of these rare and debilitating kidney diseases.Per the data readout, seven patients in the phase II NOBLE study, representing 64% of ...